| Psoriasis vulgaris
Cimzia vs Zoryve Foam
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Cimzia vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Cimzia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Cimzia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cimzia
Zoryve
At A Glance
SC injection
Every 2-4 weeks
TNF-alpha inhibitor
Topical
Once daily
PDE4 inhibitor
Indications
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Psoriasis vulgaris
- Seborrheic dermatitis
- Psoriasis vulgaris
Dosing
Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).
Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.
Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.
Seborrheic dermatitis, Psoriasis vulgaris Apply a thin layer once daily to affected areas of body and/or scalp when not wet; rub in completely; for topical use only, not for ophthalmic, oral, or intravaginal use.
Contraindications
- History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)
Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression
Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma
Most common (>=1%) - Seborrheic dermatitis nasopharyngitis, nausea, headache
Most common (>=1%) - Psoriasis vulgaris headache, diarrhea, nausea, nasopharyngitis
Pharmacology
Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.
PDE4 inhibitor; roflumilast and its active N-oxide metabolite inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP; the specific mechanism(s) by which roflumilast exerts its therapeutic action is not well defined.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cimzia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Zoryve
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Cimzia
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Cimzia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cimzia.
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CimziaView full Cimzia profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.